readthroughSign in
Nov 12, 2026Quarterly update

Grace Therapeutics details GTx-104 manufacturing fix after FDA complete response letter

The company says FDA meeting minutes showed no clinical issues with GTx-104, and it is pursuing a second manufacturer while cash runway extends to end of 2028.

Grace Therapeutics reported second quarter fiscal 2027 financial results on November 12, 2026, alongside an update on its lead candidate GTx-104, an injectable nimodipine formulation for aneurysmal subarachnoid hemorrhage (aSAH) that has completed a Phase 3 clinical trial and is being developed for IV infusion in aSAH patients to address significant unmet medical needs.1

The company received FDA meeting minutes from a Type A meeting held to discuss the Complete Response Letter issued on April 23, 2026. According to the release, the FDA did not identify any clinical safety or efficacy deficiencies and did not request additional clinical data.1 Grace said it continues work on its previously disclosed remediation plan and will provide updates as milestones are met.

To address potential issues at its current contract manufacturer, the company is pursuing parallel manufacturing paths. The company said its current CMO has responded to the FDA, submitted a corrective action plan, and is believed to be executing that plan in direct communication with the FDA, though reinspection timing depends on the CMO's readiness and FDA scheduling.1 At the same time, technology transfer began during the quarter to a second, U.S.-based CMO, starting with analytical method transfer, and the company also started required non-clinical studies.1 NDA resubmission may be supported by either CMO, or both, with timing reflecting whichever pathway reaches readiness first.1

On financing, Grace completed a $10 million private placement with institutional and accredited investors1 during the quarter, with net proceeds to the company of $9.2 million.1 Cash and cash equivalents stood at $21.3 million as of September 30, 2026, up $4.3 million from $17.0 million at March 31, 2026.1 The company said its existing cash and cash equivalents will be sufficient to sustain planned operations, including CRL-related activities, through the end of calendar 2028.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.